Press Release

Seraxis Announces FDA IND Allowance for Clinical Study of SR-02 Replacement Islets for Type 1 Diabetes

admin

October 15, 2024

About Seraxis, Inc.

Seraxis is a private biotechnology company launched in 2013 and located in Germantown, Maryland. The Seraxis mission is to develop a practical and potent cell replacement therapy for insulin-dependent diabetes.

Seraxis Announces FDA IND Allowance for Clinical Study of SR-02 Replacement Islets for Type 1 Diabetes

About Seraxis, Inc.

ENDPOINTS NEWS: Maryland biotech gets green light for stem cell-derived therapy for diabetes, aiming to compete with Vertex

Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated T1D Biotech Company

Related articles

Seraxis Announced Closing of $40M Series C Financing Round.

Seraxis Announces Publication of Preclinical Data for a Novel Islet Replacement Therapy and Clinical Candidate SR-02 for Insulin-Requiring Diabetes; Oral Presentation at IPITA.

Seraxis Inc. announces novel method and cell line that generate highly pure populations of insulin-producing cells capable of reversing diabetes in rodents.